The ABHD16A Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the human Huh-7 hepatocellular carcinoma line, designed to disrupt the ABHD16A gene. This knockout model eliminates lysophosphatidylserine (lyso-PS) lipase activity, leading to accumulation of the bioactive lipid lyso-PS. As a polyclonal pool, this product provides a heterogeneous loss-of-function system ideal for studying ABHD16A-dependent signaling without the biases of single-cell cloning, enabling robust population-level analyses in a liver cancer context.
Huh-7 cells originate from a well-differentiated hepatocellular carcinoma of a 57-year-old Japanese male. These adherent epithelial cells retain key hepatocyte functions, including metabolic activity and protein secretion, making them a widely used host for hepatitis C virus research and drug metabolism studies. Their hepatocellular origin renders them particularly relevant for investigating lipid signaling pathways and tumor-microenvironment interactions intrinsic to liver biology. The Huh-7 background thus offers a physiologically appropriate platform for dissecting the roles of ABHD16A in hepatic pathophysiology.
ABHD16A encodes a lyso-PS lipase that hydrolyzes lyso-PS, a signaling lipid that activates the G-protein-coupled receptors GPR34 and P2Y10. Disruption of ABHD16A leads to elevated lyso-PS levels, which in turn stimulate these receptors and their downstream cascades, including cAMP modulation, calcium mobilization, and MAPK/ERK phosphorylation. This signaling axis is regulated upstream by pro-inflammatory stimuli such as TNF-?? and Toll-like receptor agonists, and it ultimately influences immune cell chemotaxis and inflammatory responses. While direct interacting partners of ABHD16A remain poorly defined, functional interplay with other ABHD family proteins is plausible.
In Huh-7 cells, ABHD16A knockout creates a unique model for exploring how lyso-PS-mediated GPCR signaling intersects with hepatocellular carcinoma biology. Accumulated lyso-PS can modify the tumor microenvironment by altering immune cell recruitment and paracrine communication, potentially impacting cancer progression and drug response. This system allows researchers to interrogate lipid-driven immune modulation in a well-characterized hepatic cell line, bridging the gap between lipidomics and liver cancer immunology.
This polyclonal knockout cell population is suitable for a broad range of experimental approaches, including western blotting and RT-qPCR to confirm gene disruption, lipidomics to quantify lyso-PS changes, and GPCR activity assays measuring cAMP and calcium flux. Functional studies can employ cell migration assays, immunofluorescence, flow cytometry, and drug sensitivity screens to assess the impact on immune cell chemotaxis and therapeutic response. The model supports investigations into ABHD16A deficiency, lyso-PS pathway inhibitor screening, and the role of lipid signaling in hepatocellular carcinoma. For further technical information or to discuss this product, please contact Ascent Research.
